Literature DB >> 25767079

Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study.

Ronald B Postuma1, Alex Iranzo, Birgit Hogl, Isabelle Arnulf, Luigi Ferini-Strambi, Raffaele Manni, Tomoyuki Miyamoto, Wolfgang Oertel, Yves Dauvilliers, Yo-El Ju, Monica Puligheddu, Karel Sonka, Amelie Pelletier, Juan Santamaria, Birgit Frauscher, Smaranda Leu-Semenescu, Marco Zucconi, Michele Terzaghi, Masayuki Miyamoto, Marcus M Unger, Bertrand Carlander, Maria-Livia Fantini, Jacques Y Montplaisir.   

Abstract

OBJECTIVE: To assess whether risk factors for Parkinson disease and dementia with Lewy bodies increase rate of defined neurodegenerative disease in idiopathic rapid eye movement (REM) sleep behavior disorder (RBD).
METHODS: Twelve centers administered a detailed questionnaire assessing risk factors for neurodegenerative synucleinopathy to patients with idiopathic RBD. Variables included demographics, lifestyle factors, pesticide exposures, occupation, comorbid conditions, medication use, family history, and autonomic/motor symptoms. After 4 years of follow-up, patients were assessed for dementia or parkinsonism. Disease risk was assessed with Kaplan-Meier analysis, and epidemiologic variables were compared between convertors and those still idiopathic using logistic regression.
RESULTS: Of 305 patients, follow-up information was available for 279, of whom 93 (33.3%) developed defined neurodegenerative disease. Disease risk was 25% at 3 years and 41% after 5 years. Patients who converted were older (difference = 4.5 years, p < 0.001), with similar sex distribution. Neither caffeine, smoking, nor alcohol exposure predicted conversion. Although occupation was similar between groups, those who converted had a lower likelihood of pesticide exposure (occupational insecticide = 2.3% vs 9.0%). Convertors were more likely to report family history of dementia (odds ratio [OR] = 2.09), without significant differences in Parkinson disease or sleep disorders. Medication exposures and medical history were similar between groups. Autonomic and motor symptoms were more common among those who converted. Risk factors for primary dementia and parkinsonism were generally similar, except for a notably higher clonazepam use in dementia convertors (OR = 2.6).
INTERPRETATION: Patients with idiopathic RBD are at very high risk of neurodegenerative synucleinopathy. Risk factor profiles between convertors and nonconvertors have both important commonalities and differences.
© 2015 American Neurological Association.

Entities:  

Mesh:

Year:  2015        PMID: 25767079      PMCID: PMC5769479          DOI: 10.1002/ana.24385

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

1.  Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease.

Authors:  Silvia Rios Romenets; Jean-Francois Gagnon; Véronique Latreille; Michel Panniset; Sylvain Chouinard; Jacques Montplaisir; Ronald B Postuma
Journal:  Mov Disord       Date:  2012-06-25       Impact factor: 10.338

2.  Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Authors: 
Journal:  Mov Disord       Date:  2013-09-30       Impact factor: 10.338

3.  Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder.

Authors:  B F Boeve; M H Silber; T J Ferman; S C Lin; E E Benarroch; A M Schmeichel; J E Ahlskog; R J Caselli; S Jacobson; M Sabbagh; C Adler; B Woodruff; T G Beach; A Iranzo; E Gelpi; J Santamaria; E Tolosa; C Singer; D C Mash; C Luca; I Arnulf; C Duyckaerts; C H Schenck; M W Mahowald; Y Dauvilliers; N R Graff-Radford; Z K Wszolek; J E Parisi; B Dugger; M E Murray; D W Dickson
Journal:  Sleep Med       Date:  2013-03-07       Impact factor: 3.492

Review 4.  Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.

Authors:  Bruno Dubois; David Burn; Christopher Goetz; Dag Aarsland; Richard G Brown; Gerald A Broe; Dennis Dickson; Charles Duyckaerts; Jefferey Cummings; Serge Gauthier; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Yoshikuni Mizuno; Ian G McKeith; C Warren Olanow; Werner Poewe; Cristina Sampaio; Eduardo Tolosa; Murat Emre
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

5.  Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder.

Authors:  R B Postuma; J F Gagnon; M Vendette; M L Fantini; J Massicotte-Marquez; J Montplaisir
Journal:  Neurology       Date:  2008-12-24       Impact factor: 9.910

6.  Risk factors for dementia with Lewy bodies: a case-control study.

Authors:  Brendon P Boot; Carolyn F Orr; J Eric Ahlskog; Tanis J Ferman; Rosebud Roberts; Vernon S Pankratz; Dennis W Dickson; Joseph Parisi; Jeremiah A Aakre; Yonas E Geda; David S Knopman; Ronald C Petersen; Bradley F Boeve
Journal:  Neurology       Date:  2013-07-26       Impact factor: 9.910

7.  Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies.

Authors:  Ronald B Postuma; Jean-Francois Gagnon; Amélie Pelletier; Jacques Montplaisir
Journal:  Mov Disord       Date:  2013-03-28       Impact factor: 10.338

8.  Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.

Authors:  C H Schenck; J Y Montplaisir; B Frauscher; B Hogl; J-F Gagnon; R Postuma; K Sonka; P Jennum; M Partinen; I Arnulf; V Cochen de Cock; Y Dauvilliers; P-H Luppi; A Heidbreder; G Mayer; F Sixel-Döring; C Trenkwalder; M Unger; P Young; Y K Wing; L Ferini-Strambi; R Ferri; G Plazzi; M Zucconi; Y Inoue; A Iranzo; J Santamaria; C Bassetti; J C Möller; B F Boeve; Y Y Lai; M Pavlova; C Saper; P Schmidt; J M Siegel; C Singer; E St Louis; A Videnovic; W Oertel
Journal:  Sleep Med       Date:  2013-07-22       Impact factor: 4.842

9.  Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients.

Authors:  Alex Iranzo; Ana Fernández-Arcos; Eduard Tolosa; Mónica Serradell; José Luis Molinuevo; Francesc Valldeoriola; Ellen Gelpi; Isabel Vilaseca; Raquel Sánchez-Valle; Albert Lladó; Carles Gaig; Joan Santamaría
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

10.  REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease.

Authors:  Michal Rolinski; Konrad Szewczyk-Krolikowski; Paul R Tomlinson; Kannan Nithi; Kevin Talbot; Yoav Ben-Shlomo; Michele Tm Hu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-11-01       Impact factor: 10.154

View more
  70 in total

1.  Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease.

Authors:  Shahmir Sohail; Lei Yu; Julie A Schneider; David A Bennett; Aron S Buchman; Andrew S P Lim
Journal:  Mov Disord       Date:  2017-10-30       Impact factor: 10.338

Review 2.  Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies.

Authors:  Daniel A Barone; Claire Henchcliffe
Journal:  Clin Neurophysiol       Date:  2018-05-29       Impact factor: 3.708

Review 3.  Mechanistic insights into the pathogenesis of neurodegenerative diseases: towards the development of effective therapy.

Authors:  Fauzia Nazam; Sibhghatulla Shaikh; Nazia Nazam; Abdulaziz Saad Alshahrani; Gulam Mustafa Hasan; Md Imtaiyaz Hassan
Journal:  Mol Cell Biochem       Date:  2021-03-09       Impact factor: 3.396

4.  The Alzheimer's Prevention Clinic at Weill Cornell Medical College / New York - Presbyterian Hospital: Risk Stratification and Personalized Early Intervention.

Authors:  A Seifan; R Isaacson
Journal:  J Prev Alzheimers Dis       Date:  2015-10-01

5.  Natural history of pure autonomic failure: A United States prospective cohort.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma; Italo Biaggioni; Phillip A Low; Wolfgang Singer; David S Goldstein; Amanda C Peltier; Cyndia A Shibao; Christopher H Gibbons; Roy Freeman; David Robertson
Journal:  Ann Neurol       Date:  2017-02       Impact factor: 10.422

6.  Brain pathway differences between Parkinson's disease patients with and without REM sleep behavior disorder.

Authors:  Mina Ansari; Farzaneh Rahmani; Mahsa Dolatshahi; Atefe Pooyan; Mohammad Hadi Aarabi
Journal:  Sleep Breath       Date:  2016-11-16       Impact factor: 2.816

7.  What the "man in the moon" can tell us about the future of our brains.

Authors:  Birgit Högl
Journal:  Ann Transl Med       Date:  2017-09

8.  An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease.

Authors:  Lidia Sarro; Nirubol Tosakulwong; Christopher G Schwarz; Jonathan Graff-Radford; Scott A Przybelski; Timothy G Lesnick; Samantha M Zuk; Robert I Reid; Mekala R Raman; Bradley F Boeve; Tanis J Ferman; David S Knopman; Giancarlo Comi; Massimo Filippi; Melissa E Murray; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Clifford R Jack; Kejal Kantarci
Journal:  Alzheimers Dement       Date:  2016-08-10       Impact factor: 21.566

9.  Effect of serum uric acid on cognition in patients with idiopathic REM sleep behavior disorder.

Authors:  Xudong Li; Shuhong Jia; Zhi Zhou; Yi Jin; Xiangfei Zhang; Chunlei Hou; Wenjing Zheng; Pei Rong; Jinsong Jiao
Journal:  J Neural Transm (Vienna)       Date:  2018-10-03       Impact factor: 3.575

10.  The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder.

Authors:  Ziv Gan-Or; Noreen Mohsin; Simon L Girard; Jacques Y Montplaisir; Amirthagowri Ambalavanan; Stephanie Strong; Victoria Mallett; Sandra B Laurent; Cynthia V Bourassa; Michel Boivin; Melanie Langlois; Isabelle Arnulf; Birgit Högl; Birgit Frauscher; Christelle Monaca; Alex Desautels; Jean-François Gagnon; Ronald B Postuma; Patrick A Dion; Yves Dauvilliers; Nicolas Dupre; Roy N Alcalay; Guy A Rouleau
Journal:  Neurobiol Aging       Date:  2016-04-06       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.